---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020819"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:12:32.090024+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aeglea BioTherapeutics reports Q1 2023 net loss of $18.4M; cash at $39.8M

## Summary
- Cash, equivalents, marketable securities, restricted cash totaled $39.8M as of March 31, 2023.
- Revenue of $0.2M from Immedica Pharma license/supply agreement for pegzilarginase in Europe/Middle East.
- R&D expenses fell to $13.8M from $17.0M; G&A expenses fell to $5.2M from $8.8M year-over-year.
- Net loss improved to $18.4M from $24.4M in Q1 2022; includes $1.7M non-cash stock compensation.

## SEC filing metadata
- accession: 0000950170-23-020819
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000095017023020819/0000950170-23-020819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000095017023020819/agle-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020819
- JSON: https://secwatch.observer/filing/0000950170-23-020819.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020819.txt

## Key facts
- Earnings Releases
  Spyre Therapeutics, Inc. reported first quarter 2023 results: revenue $0.2 million, net income Net loss totaled $18.4 million.
  - Period: first quarter 2023
  - Revenue: $0.2 million
  - Net income: Net loss totaled $18.4 million
  - Result: reported results
  source text: 31, 2023, Aeglea had available cash and cash equivalents, marketable securities and restricted cash of $39.8 million. Aeglea recognized development fee and royalty revenues of $0.2 million in the first quarter of 2023, as a result of its license and supply agreement with Immedica Pharma AB for the commercial rights to pegzilarginase in Europe and several countries
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000095017023020819/0000950170-23-020819-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.